Seat­tle's Nohla clos­es $45M to bring nov­el stem cell treat­ment for leukemia to late-stage tri­als

Seat­tle’s Nohla Ther­a­peu­tics, a biotech start­up spun out of the Fred Hutchin­son Can­cer Re­search Cen­ter, has raised $45 mil­lion in new mon­ey to push for­ward its Phase II cell ther­a­py for cord blood trans­plants.

The new Se­ries B, backed in part by Cel­gene $CELG and Fi­deli­ty, brings the com­pa­ny’s to­tal haul to $88.5 mil­lion since Nohla’s 2015 launch.

The com­pa­ny is de­vel­op­ing a cel­lu­lar tech­nol­o­gy plat­form first in­vent­ed by the com­pa­ny’s co-founder and CMO Colleen De­laney. First up, the start­up is tack­ling a nov­el stem cell treat­ment for leukemia that us­es cells from do­nat­ed um­bil­i­cal cord blood. It could be more ef­fec­tive than tra­di­tion­al bone mar­row trans­plants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.